Integra LifeSciences Guides 3Q Revenue to $410M-$412M
IART sits 85% above its 52-week low of $8.7.
Summary
Integra LifeSciences issued preliminary third quarter results, guiding 3Q revenue to $410M-$412M and 3Q adjusted EPS to 55c-59c. The company also updated full-year 2026 guidance, cutting its FY26 sales and EPS outlook from a previous revenue range of $1.65B-$1.70B. This follows Q2 results where the company swung to a profit and reaffirmed full-year guidance, but also disclosed a flood at its Cincinnati plant that could disrupt operations. The 3Q revenue range provides a concrete near-term target and will be compared against consensus estimates. The guidance suggests management expects continued revenue momentum despite the operational disruption. Investors will watch for any commentary on the flood's impact when 3Q results are reported.
Updates
· SEC 8-K — Integra expects Q4 revenue impact of $15M-$20M from the Cincinnati flood and full manufacturing recovery in Q2 2027; FY26 revenue guidance cut to $1.634B-$1.654B and adjusted EPS to $2.30-$2.40.
- Flood Impact — Flooding at the Cincinnati facility in July 2026 caused damage to portions of the facility, equipment, inventory and other assets, negatively impacting third quarter revenue by approximately $7 million.
- Insurance Recoveries — Integra maintains property and business interruption insurance covering the Cincinnati facility and expects insurance recoveries to mitigate a substantial portion of the earnings impact throughout the recovery period until full manufacturing capacity returns.
- Mitigation Actions — Company utilized available inventory, activated established alternate sources of supply for certain products, and advanced restoration activities at the Cincinnati facility.
- Cash Flow — Integra expects third quarter operating cash flow to be greater than $85 million and full-year 2026 operating cash flow to be approximately $190 million to $200 million.
- FY26 EPS Guidance — Updated full-year 2026 adjusted EPS guidance from a previous range of $2.40 to $2.50.
All 8 details
- Integra expects third quarter operating cash flow to be greater than $85 million.
- Flooding negatively impacted third quarter revenue by approximately $7 million.
- Updated full-year 2026 adjusted EPS guidance from a previous range of $2.40 to $2.50.
- Expects full-year 2026 operating cash flow to be approximately $190 million to $200 million.
- Company expects insurance recoveries to mitigate a substantial portion of the earnings impact.
- Flooding at the Cincinnati facility in July 2026 caused damage to portions of the facility, equipment, inventory and other assets.
- Integra maintains property and business interruption insurance covering the Cincinnati facility; expects insurance recoveries to mitigate a substantial portion of the earnings impact throughout the recovery period until full manufacturing capacity returns.
- Company utilized available inventory, activated established alternate sources of supply for certain products, and advanced restoration activities at the Cincinnati facility.
At the time of this announcement, IART was trading at $16.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $8.70 to $20.49. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.